CNBC December 11, 2025
Key Points
– Ahead of its Capital Markets Day Thursday, Zealand Pharma unveiled its “Metabolic Frontier 2030” strategy.
– The strategy comes as Zealand shares have dropped 29% year to date, with investors betting on the weight loss drug market to fragment.
– The company also announced an agreement with Chinese biotech firm OTR Therapeutics to develop oral small molecule treatments for metabolic diseases.
Zealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more of these medicines near market entry.
The new strategy, “Metabolic Frontier 2030,” comes as Zealand shares have dropped 29% year to...
Today's Sponsors
Today's Sponsor